Fulcrum Therapeutics Stock News

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -1.59% and 24.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the st

Fulcrum Therapeutics, Inc. (FULC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street ana

Investors need to pay close attention to Fulcrum (FULC) stock based on the movements in the options market lately.

Fulcrum Therapeutics, Inc. (FULC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the

Event to discuss unmet need in FSHD, key measures of disease progression and Phase 3 REACH trial

Oppenheimer has started the coverage on the clinical-stage biopharmaceutical company Fulcrum Therapeutics (FULC) with an Outperform recommendation citing the potential of FTX-6058,…

The average of price targets set by Wall Street analysts indicates a potential upside of 178.8% in Fulcrum Therapeutics, Inc. (FULC). While the effectiveness of this highly sought-after metric is ques

Fulcrum Therapeutics Inc (NASDAQ: FULC ) plans to initiate REACH, a Phase 3 trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD), in Q2 of 2022 . FSHD is characterized by fat infiltration of skeletal muscle leading to muscular atrophy involving the face, scapula and shoulders, upper arms, and abdomen. REACH will be a randomized, double-blind, placebo-controlled, multi-national trial to evaluate the efficacy and safety of … Full story available on Benzinga.com

Fulcrum Therapeutics (FULC) plans to begin a phase 3 trial, called REACH, of losmapimod in people with facioscapulohumeral muscular dystrophy ((FSHD)) in Q2 2022.FSHD is a rare…

Fulcrum Therapeutics press release (FULC): Q4 GAAP EPS of -$0.58 beats by $0.09.Revenue of $5.06M (+19.6% Y/Y) beats by $1.54M.CEO comment We announced today that we have a…

– Clear path forward for Phase 3 REACH trial with losmapimod in FSHD; Trial expected to begin in 2Q 2022 –

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 10.77% and 26.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

Companies Reporting Before The Bell • Travelzoo (NASDAQ: TZOO ) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban One (NASDAQ: UONEK ) is likely to report earnings for its fourth quarter. • Tile Shop Holdings (NASDAQ: TTSH ) is likely to report earnings for its fourth quarter. • Oxford Square Capital (NASDAQ: OXSQ ) is estimated to report quarterly earnings at $0.09 per share on revenue of $10.30 million. • Aurora Mobile (NASDAQ: JG ) is projected to report quarterly loss at $0.07 per share on revenue of $15.65 million. • Mobile TeleSystems (NYSE: MBT ) is estimated to report quarterly earnings at $0.19 per share on revenue of $1.69 billion. • LENSAR (NASDAQ: LNSR ) is estimated to report quarterly loss at $0.52 per share on revenue of $8.70 million. • Bluegreen Vacations (NYSE: BVH ) is likely to report quarterly earnings at $0.62 per share on revenue of $203.89 million. • Fulcrum Therapeutics (NASDAQ: FULC ) is projected to report quarterly loss at $0.

Fulcrum Therapeutics (FULC) granted inducement awards outside of its 2019 Stock Incentive Plan to its newly appointed VP, Head of Market Value, Access and Policy Amy Winnen.The…